Unmet Diagnostic and Therapeutic Opportunities for Chronic Obstructive Pulmonary Disease in Low- and Middle-Income Countries

Abstract

Rationale: Chronic obstructive pulmonary disease (COPD) is a prevalent and burdensome condition in low- and middle-income countries (LMICs). Challenges to better care include more effective diagnosis and access to affordable interventions. There are no previous reports describing therapeutic needs of populations with COPD in LMICs who were identified through screening. Objectives: To describe unmet therapeutic need in screening-detected COPD in LMIC settings. Methods: We compared interventions recommended by the international Global Initiative for Chronic Obstructive Lung Disease COPD strategy document, with that received in 1,000 people with COPD identified by population screening at three LMIC sites in Nepal, Peru, and Uganda. We calculated costs using data on the availability and affordability of medicines. Measurement and Main Results: The greatest unmet need for nonpharmacological interventions was for education and vaccinations (applicable to all), pulmonary rehabilitation (49%), smoking cessation (30%), and advice on biomass smoke exposure (26%). Ninety-five percent of the cases were previously undiagnosed, and few were receiving therapy (4.5% had short-acting β-agonists). Only three of 47 people (6%) with a previous COPD diagnosis had access to drugs consistent with recommendations. None of those with more severe COPD were accessing appropriate maintenance inhalers. Even when available, maintenance treatments were unaffordable, with 30 days of treatment costing more than a low-skilled worker's daily average wage. Conclusions: We found a significant missed opportunity to reduce the burden of COPD in LMIC settings, with most cases undiagnosed. Although there is unmet need in developing novel therapies, in LMICs where the burden is greatest, better diagnosis combined with access to affordable interventions could translate to immediate benefit.

Keywords: COPD; LMIC; bronchodilator; guidelines; pulmonary rehabilitation.

Figure 1.

Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2022 group, concordance with pharmacotherapy recommendations, and eligibility for nonpharmacological interventions for 999 people with COPD. A random sample of 10,664 people over 40 years of age was collected at three sites in Nepal, Peru, and Uganda. In the 2023 update to GOLD guidance, groups C and D have been combined as group E. Percentages are indicated on the y-axis. COPD = chronic obstructive pulmonary disease.

Figure 1.

Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2022 group, concordance with pharmacotherapy recommendations, and eligibility for nonpharmacological interventions for 999 people with COPD. A random sample of 10,664 people over 40 years of age was collected at three sites in Nepal, Peru, and Uganda. In the 2023 update to GOLD guidance, groups C and D have been combined as group E. Percentages are indicated on the y-axis. COPD = chronic obstructive pulmonary disease.